Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics (Nasdaq: ARTV) has appointed Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, with expertise in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. and was formerly CTO of Allogene Therapeutics.
Fred Aslan, M.D., CEO of Artiva, highlighted Dr. Moore's extensive experience in manufacturing and technical operations, particularly in allogeneic cell therapies. The company believes its manufacturing process for AlloNK® sets it apart from peers, potentially accelerating the path to bring this experimental therapy to patients with autoimmune diseases and cancers.
Dr. Moore expressed enthusiasm for AlloNK®'s scalable and robust manufacturing process, noting its simplified approach due to the lack of genetic engineering. She aims to help realize the full potential of AlloNK® in treating autoimmune diseases and cancer.
Artiva Biotherapeutics (Nasdaq: ARTV) ha nominato Alison Moore, Ph.D., come membro indipendente del suo Consiglio di Amministrazione. La Dott.ssa Moore porta oltre 25 anni di esperienza esecutiva nell'industria della biotecnologia e dei farmaci, con competenze nella produzione di terapie cellulari. Attualmente ricopre il ruolo di Chief Technical Officer (CTO) di Codexis Inc. ed è stata in precedenza CTO di Allogene Therapeutics.
Fred Aslan, M.D., CEO di Artiva, ha sottolineato l'ampia esperienza della Dott.ssa Moore nella produzione e nelle operazioni tecniche, in particolare nelle terapie cellulari allogeniche. L'azienda crede che il suo processo di produzione per AlloNK® la distingua dai concorrenti, potenzialmente accelerando il percorso per portare questa terapia sperimentale ai pazienti affetti da malattie autoimmuni e tumori.
La Dott.ssa Moore ha espresso entusiasmo per il processo di produzione scalabile e robusto di AlloNK®, notando il suo approccio semplificato grazie all'assenza di ingegneria genetica. Il suo obiettivo è aiutare a realizzare il pieno potenziale di AlloNK® nel trattamento delle malattie autoimmuni e del cancro.
Artiva Biotherapeutics (Nasdaq: ARTV) ha nombrado a Alison Moore, Ph.D., como miembro independiente de su Junta Directiva. La Dra. Moore aporta más de 25 años de experiencia ejecutiva en la industria de la biotecnología y los productos farmacéuticos, con especialización en la fabricación de terapias celulares. Actualmente es Directora Técnica (CTO) de Codexis Inc. y fue anteriormente CTO de Allogene Therapeutics.
Fred Aslan, M.D., CEO de Artiva, destacó la amplia experiencia de la Dra. Moore en la producción y las operaciones técnicas, especialmente en terapias celulares alogénicas. La empresa cree que su proceso de fabricación para AlloNK® la distingue de sus pares, lo que podría acelerar el camino para llevar esta terapia experimental a pacientes con enfermedades autoinmunes y cánceres.
La Dra. Moore expresó su entusiasmo por el proceso de fabricación escalable y robusto de AlloNK®, señalando su enfoque simplificado debido a la ausencia de ingeniería genética. Su objetivo es ayudar a realizar todo el potencial de AlloNK® en el tratamiento de enfermedades autoinmunes y cáncer.
Artiva Biotherapeutics (Nasdaq: ARTV)는 Alison Moore, Ph.D.를 이사회의 독립 이사로 임명했습니다. Moore 박사는 세포 치료 제조 분야의 전문성을 가지고 있는 생명공학 및 제약 산업에서 25년 이상의 경영 경험을 가지고 있습니다. 현재 그녀는 Codexis Inc.의 최고 기술 책임자(CTO)로 재직 중이며, 이전에는 Allogene Therapeutics의 CTO를 역임했습니다.
Artiva의 CEO인 Fred Aslan 박사는 Moore 박사의 제조 및 기술 운영에 대한 광범위한 경험, 특히 동종세포 치료에 대해 강조했습니다. 이 회사는 AlloNK®의 제조 공정이 동종 업계와 차별화되어 있으며, 이는 자가 면역 질환 및 암 환자에게 이 실험적 치료를 제공하는 경로를 가속화할 수 있다고 믿고 있습니다.
Moore 박사는 AlloNK®의 확장 가능하고 견고한 제조 공정에 대한 열정을 표현하며, 유전자 조작의 부재로 인해 단순화된 접근 방식을 주목했습니다. 그녀는 자가 면역 질환과 암 치료에서 AlloNK®의 잠재력을 완전히 실현하는 데 도움이 되고자 합니다.
Artiva Biotherapeutics (Nasdaq: ARTV) a nommé Alison Moore, Ph.D., comme membre indépendant de son conseil d'administration. Dr. Moore apporte plus de 25 ans d'expérience exécutive dans l'industrie de la biotechnologie et des produits pharmaceutiques, avec une expertise en fabrication de thérapies cellulaires. Elle occupe actuellement le poste de Directrice Technique (CTO) chez Codexis Inc. et a été auparavant CTO d'Allogene Therapeutics.
Fred Aslan, M.D., PDG d'Artiva, a souligné l'expérience étendue de Dr. Moore en matière de fabrication et d'opérations techniques, en particulier dans les thérapies cellulaires allogéniques. L'entreprise croit que son processus de fabrication pour AlloNK® la distingue de ses pairs, pouvant potentiellement accélérer le chemin pour amener cette thérapie expérimentale aux patients atteints de maladies auto-immunes et de cancers.
Dr. Moore a exprimé son enthousiasme pour le processus de fabrication évolutif et robuste d'AlloNK®, notant son approche simplifiée en raison de l'absence de génie génétique. Elle vise à aider à réaliser tout le potentiel d'AlloNK® dans le traitement des maladies auto-immunes et du cancer.
Artiva Biotherapeutics (Nasdaq: ARTV) hat Alison Moore, Ph.D., als unabhängiges Mitglied seines Vorstands berufen. Dr. Moore bringt über 25 Jahre Führungserfahrung in der Biotechnologie- und Pharmaindustrie mit, insbesondere in der Herstellung von Zelltherapien. Derzeit ist sie Chief Technical Officer (CTO) von Codexis Inc. und war zuvor CTO von Allogene Therapeutics.
Fred Aslan, M.D., CEO von Artiva, hob Dr. Moores umfangreiche Erfahrung in der Herstellung und in technischen Operationen, insbesondere in allogenen Zelltherapien, hervor. Das Unternehmen glaubt, dass der Herstellungsprozess von AlloNK® es von anderen Wettbewerbern abhebt und möglicherweise den Weg beschleunigt, diesen experimentellen Therapieansatz Patienten mit Autoimmunerkrankungen und Krebs zugänglich zu machen.
Dr. Moore äußerte ihre Begeisterung für den skalierbaren und robusten Herstellungsprozess von AlloNK® und bemerkte den vereinfachten Ansatz aufgrund des Fehlens genetischer Veränderungen. Ihr Ziel ist es, das volle Potenzial von AlloNK® bei der Behandlung von Autoimmunerkrankungen und Krebs zu realisieren.
- Appointment of Alison Moore, Ph.D., with 25+ years of industry experience to the Board of Directors
- Dr. Moore's expertise in cell therapy manufacturing aligns with Artiva's focus on allogeneic cell therapies
- AlloNK®'s manufacturing process is considered scalable and robust, potentially accelerating development
- Lack of genetic engineering in AlloNK® simplifies the manufacturing process
- None.
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (Nasdaq: CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (Nasdaq: ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies.
“We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and technical operations across modalities, specifically in allogenic cell therapies, will bring an important perspective to our team as we advance our pipeline in the clinic,” said Fred Aslan, M.D., CEO of Artiva. “In parallel to our efforts to evaluate the efficacy and safety of AlloNK®, we believe the extensive history of our manufacturing process sets us apart from our allogeneic cell therapy peers, potentially accelerating our path to bring this experimental therapy to patients."
Dr. Moore added, “I have been impressed with the scalability and robustness of AlloNK®’s manufacturing process at this stage of development. Built on a decade of leadership, the lack of genetic engineering simplifies the manufacturing process, and the clinical experience to date suggests this therapy offers a compelling approach to depleting B cells and potentially addressing the unmet need for patients with devastating autoimmune diseases and cancers. I am excited to join the board at this critical point in Artiva’s evolution to help realize the full potential of AlloNK® for the treatment of autoimmune disease and cancer.”
Prior to Codexis and Allogene, Dr. Moore spent 20 years at Amgen, most recently as Senior Vice President of Process Development, with leadership roles in Supply Chain and Manufacturing. Before joining Amgen, she held positions at Genentech in chemistry, manufacturing and regulatory affairs. Dr. Moore holds a bachelor’s degree in pharmacology with Honors and a Ph.D. in Cell Biology from Manchester University, England.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the potential benefits, accessibility, effectiveness and safety of AlloNK® and Artiva’s manufacturing strategy. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
FAQ
Who is the new Board member appointed by Artiva Biotherapeutics (ARTV)?
What is Dr. Alison Moore's current role outside of Artiva Biotherapeutics (ARTV)?
What is AlloNK® and how does it relate to Artiva Biotherapeutics (ARTV)?
How might Dr. Moore's appointment benefit Artiva Biotherapeutics (ARTV)?
